ABL1 and infection: Neither chronic phase CML nor BCR-ABL tyrosine kinase inhibitors (TKIs) induce significant immune suppression and there has been no data suggesting that CML patients in first chronic phase may be at higher risk of infection by the novel coronavirus than the general population.